Table 2.
Characteristics of eligible patients divided by the severity of albuminuria not specified in Table 1
| Normoalbuminuria | Microalbuminuria | Macroalbuminuria | P-value | |
|---|---|---|---|---|
| n = 186 472 | n = 107 170 | n = 34 357 | ||
| White blood cell (/µL)a | 6200 (5100-7400) | 6500 (5400-7800) | 6800 (5700-8200) | <.001 |
| Red blood cell (104/µL)a | 451 (414-487) | 443 (402-485) | 428 (380-477) | <.001 |
| Hematocrit (%)a | 41.6 (38.6-44.7) | 40.9 (37.4-44.4) | 39.3 (35.1-43.5) | <.001 |
| Mean corpuscular volume (fL)a | 0.924 (0.893-0.956) | 0.924 (0.893-0.957) | 0.919 (0.886-0.953) | <.001 |
| Platelet (104/µL)a | 21.4 (17.9-25.5) | 21.4 (17.6-25.5) | 21.8 (17.8-26.1) | <.001 |
| Antineoplastic use | 10 068 (5.4%) | 6083 (5.7%) | 2084 (6.1%) | <.001 |
| Anti-infective use | 30 825 (16.5%) | 21 106 (19.7%) | 8720 (25.4%) | <.001 |
| Antithrombotic use | 79 309 (42.5%) | 54 129 (50.5%) | 20 826 (60.6%) | <.001 |
| H2 blocker use | 9823 (5.3%) | 6833 (6.4%) | 2453 (7.1%) | <.001 |
| Proton pump inhibitor use | 44 441 (23.8%) | 30 615 (28.6%) | 10 962 (31.9%) | <.001 |
| Antacid use | 29 272 (15.7%) | 17 886 (16.7%) | 6509 (18.9%) | <.001 |
| NSAID use | 22 070 (11.8%) | 13 133 (12.3%) | 4042 (11.8%) | .002 |
| Antirheumatic use | 601 (0.3%) | 300 (0.3%) | 78 (0.2%) | .004 |
| Systemic corticosteroid use | 15 225 (8.2%) | 8580 (8.0%) | 3076 (9.0%) | <.001 |
Abbreviations: NSAID, nonsteroid anti-inflammatory drug.
Data are presented as median (1st-3rd quantile) for continuous measures and n (%) for categorical measures.
a Data are shown among those with white blood cell levels available (n = 325 494), red blood cell levels available (n = 325 542), hematocrit levels available (n = 327 615), Mean corpuscular volume levels available (n = 325 273), platelet levels available (n = 325 457).